| Galapagos NV |
| Date/Time | / |
| Chg. / Chg.(%) | - / |
| Bid | - |
| Ask | - |
| Open | - |
| Previous Close | - |
| High | - |
| Low | - |
| Volume [EUR] | - |
| Volume [Units] | |
| Price fixings | |
| ISIN | BE0003818359 |
| Security | GLPG |
| Exchange | Euronext - Amsterdam |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 51.05 |  |
|
| Euronext - A.. | 51.21 | |
226,161 |
| Cboe Europe .. | 51.18 | |
56,545 |
| London Inter.. | 51.54 | |
53,503 |
| Turquoise | 51.20 | |
17,592 |
| TradeGate | 51.13 | |
2,634 |
| Cboe Europe .. | 51.15 | |
1,079 |
| Cboe Europe .. | 51.22 | |
205 |
| Frankfurt | 50.8500 |  |
100 |
| Düsseldorf | 51.19 | |
0 |
| München | 51.20 | |
0 |
| Xetra | 51.21 | |
0 |
| Stuttgart | 51.250 | |
0 |
| Berlin | 51.04 | |
0 |
| Vienna Globa.. | 51.20 | |
0 |
| gettex | 51.220 | |
|
| Quotrix | 50.8900 | |
|
| Nasdaq Other.. | 59.5000 | 1,000 |
News
- Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation
07/14/2021 / 22:01 - GlobeNewswire - Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
07/14/2021 / 22:01 - GlobeNewswire - Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis
07/10/2021 / 11:10 - GlobeNewswire - Amolyt Pharma Announces Appointment of Two Directors
07/08/2021 / 14:00 - GlobeNewswire - Galapagos announces departure of CSO Piet Wigerinck later this year
06/22/2021 / 22:01 - GlobeNewswire
Real-time